View Exam | PowerPak

1. The interaction between vascular endothelial growth factor (VEGF)-F and __________ is thought to be especially important in the stimulation of angiogenesis.

A. VEGF-B B. Epidermal growth factor receptor C. VEGFR2 D. VEGFR5

2. Which of the following BEST describes the mechanism of action of ramucirumab?

A. It is a monoclonal antibody that targets epidermal growth factor receptor. B. It is a monoclonal antibody that targets the extracellular domain of vascular endothelial growth factor receptor (VEGFR)-2. C. It is an oral multikinase inhibitor that inhibits several membrane-bound and intracellular kinases. D. It acts as a VEGF decoy or trap to prevent interaction of VEGF-A with its receptors.

3. According to the National Comprehensive Cancer Network guidelines, which of the following would be MOST appropriate for use in combination with 5-FU, leucovorin, and irinotecan (FOLFIRI) chemotherapy for a patient with metastatic colorectal cancer as well as disease progression on prior 5-FU, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab?

A. Nintedanib B. Ramucirumab C. Regorafenib D. An immune checkpoint inhibitor

4. A 60-year-old woman with metastatic colorectal cancer has had disease progression after first-line treatment with 5-FU, leucovorin, and oxaliplatin (FOLFOX) chemotherapy plus bevacizumab, and then again after second-line therapy on 5-FU, leucovorin, and irinotecan (FOLFIRI) plus ziv-aflibercept. Pathology reveals that her cancer has a KRAS mutation. Which of the following options would be MOST appropriate for this patient at this time?

A. Continue treating her with FOLFIRI and replace ziv-aflibercept with regorafenib B. Treat her with single-agent regorafenib C. Treat her with an immune checkpoint inhibitor D. Treat her with capecitabine and oxaliplatin (CAPEOX) chemotherapy plus famitinib

5. Which of the following BEST describes the mechanism of action of nintedanib?

A. It is a monoclonal antibody that targets vascular endothelial growth factor (VEGF)-A. B. It is a monoclonal antibody that targets the extracellular domain of vascular endothelial growth factor receptor (VEGFR)-2. C. It is an oral multikinase inhibitor of VEGF 1-3 and other kinases. D. It acts as a VEGF decoy or trap to prevent interaction of VEGF-A with its receptors.

6. Which of the following are the MOST common class-related adverse events associated with vascular endothelial growth factor (VEGF) inhibitors?

A. Fatigue and nausea B. Dermatologic reactions C. Neutropenia and thrombocytopenia D. Hypertension and thromboembolic events

7. RY is a 57-year-old man who was diagnosed with metastatic colorectal cancer and experienced disease progression on capecitabine and oxaliplatin (CAPEOX) chemotherapy plus bevacizumab. He is about to begin treatment with 5-FU, leucovorin, and irinotecan (FOLFIRI) plus ramucirumab. Which of the following premedication strategies should you recommend before RY's ramucirumab treatment?

A. Oral prednisone B. Oral ondansetron C. Intravenous histamine H1 antagonist D. No premedication is necessary with ramucirumab

8. Regular monitoring of ____________ is recommended for patients being treated with vascular endothelial growth factor (VEGF) inhibitors.

A. Creatinine clearance B. Body weight C. Blood pressure D. VEGF levels

9. TRUE or FALSE: Ramucirumab dose should be reduced by 50% when administered to patients with mild renal impairment.

A. True B. False

10. Which of the following would be MOST appropriate for a patient beginning regorafenib therapy?

A. Avoid strong CYP3A4 inducers or inhibitors B. Avoid strong CYP2C9 inducers or inhibitors C. Decrease dose by 50% when administered with CYP2D6 inhibitors D. Increase dose by 50% when administered with CYP3A4 inducers

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The interaction between vascular endothelial growth factor (VEGF)-F and __________ is thought to be especially important in the stimulation of angiogenesis.

2. Which of the following BEST describes the mechanism of action of ramucirumab?

5. Which of the following BEST describes the mechanism of action of nintedanib?

6. Which of the following are the MOST common class-related adverse events associated with vascular endothelial growth factor (VEGF) inhibitors?

8. Regular monitoring of ____________ is recommended for patients being treated with vascular endothelial growth factor (VEGF) inhibitors.

9. TRUE or FALSE: Ramucirumab dose should be reduced by 50% when administered to patients with mild renal impairment.

10. Which of the following would be MOST appropriate for a patient beginning regorafenib therapy?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The interaction between vascular endothelial growth factor (VEGF)-F and __________ is thought to be especially important in the stimulation of angiogenesis.

2. Which of the following BEST describes the mechanism of action of ramucirumab?

5. Which of the following BEST describes the mechanism of action of nintedanib?

6. Which of the following are the MOST common class-related adverse events associated with vascular endothelial growth factor (VEGF) inhibitors?

8. Regular monitoring of ____________ is recommended for patients being treated with vascular endothelial growth factor (VEGF) inhibitors.

9. TRUE or FALSE: Ramucirumab dose should be reduced by 50% when administered to patients with mild renal impairment.

10. Which of the following would be MOST appropriate for a patient beginning regorafenib therapy?

« Return to Activity

Customers who Purchased
this Activity also Purchased